Symposium on cancer genomics, Heidelberg, Germany
17 September 2011 - 17 September 2011
Germany
A symposium on cancer genomics will take place from 17 to 19 September 2011 in Heidelberg, Germany.
Cancer genomics is the study of the human cancer genome. It includes the search for the full collection of genes and mutations, both inherited and sporadic, that contribute to the development of a cancer cell and its progression from a localised cancer to one that grows uncontrolled and spreads throughout the body. A comprehensive analysis of the cancer genome remains a challenge today. There is no single technology at present that will detect all the types of abnormality--deletions, rearrangements, point mutations, frameshift insertions, amplifications, imprinting, and epigenetic changes--implicated in cancer.
Many clinical trials now include genomic profiles of cancer patients as prognostic and diagnostic indicators. Genomic profiles are even used to monitor where and how the cancer genome has been hit during molecularly targeted therapies. Mining and sharing all this data could eventually help oncologists to better integrate the genotypic and phenotypic changes that occur in a biosystem during cancer's progression. This knowledge will be used to bring earlier and better interventions to cancer patients.
This conference will provide an opportunity to learn about the progressing areas of cancer genomics. The meeting will bring together scientists to interact and stimulate future research.For further information, please visit: here(opens in new window)
Cancer genomics is the study of the human cancer genome. It includes the search for the full collection of genes and mutations, both inherited and sporadic, that contribute to the development of a cancer cell and its progression from a localised cancer to one that grows uncontrolled and spreads throughout the body. A comprehensive analysis of the cancer genome remains a challenge today. There is no single technology at present that will detect all the types of abnormality--deletions, rearrangements, point mutations, frameshift insertions, amplifications, imprinting, and epigenetic changes--implicated in cancer.
Many clinical trials now include genomic profiles of cancer patients as prognostic and diagnostic indicators. Genomic profiles are even used to monitor where and how the cancer genome has been hit during molecularly targeted therapies. Mining and sharing all this data could eventually help oncologists to better integrate the genotypic and phenotypic changes that occur in a biosystem during cancer's progression. This knowledge will be used to bring earlier and better interventions to cancer patients.
This conference will provide an opportunity to learn about the progressing areas of cancer genomics. The meeting will bring together scientists to interact and stimulate future research.For further information, please visit: here(opens in new window)